Skip to main content

Table 5 ASAS40 and BASDAI 50 response rates at week 12 in patients with AS stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

  ASAS40 BASDAI 50
  Response rate, n/N(%) Unadjusted odds ratio Pvalue Response rate, n/N(%) Unadjusted odds ratio Pvalue
   (95% CI)    (95% CI)  
History of prior anti-TNF therapy       
   Prior ETN or IFX or both 115/305 (37.7) 0.41 (0.32 to 0.54) < 0.001 128/314 (40.8) 0.40 (0.31 to 0.53) < 0.001
   No prior ETN/IFXa 518/873 (59.3)    561/890 (63.0)   
Prior TNF antagonist(s)       
   ETN only 25/81 (30.9) 0.93 (0.47 to 1.83) 0.083 27/81 (33.3) 0.98 (0.51 to 1.90) 0.033
   IFX only 66/150 (44.0) 1.64 (0.91 to 2.93)   75/156 (48.1) 1.82 (1.03 to 3.20)  
   ETN and IFXa 24/74 (32.4)    26/77 (33.8)   
Reason for discontinuation of prior TNF antagonist       
   Loss of response 46/108 (42.6) 2.09 (1.05 to 4.14) 0.108 47/112 (42.0) 2.03 (1.03 to 4.03) 0.059
   Intolerance 20/52 (38.5) 1.76 (0.79 to 3.91)   25/54 (46.3) 2.42 (1.11 to 5.30)  
   Lack of responsea 16/61 (26.2)    16/61 (26.2)   
  1. aUsed as reference value. AS, ankylosing spondylitis; ASAS40, Assessment of SpondyloArthritis international Society 40% response; BASDAI 50, Bath AS Disease Activity Index 50% response; CI, confidence interval; ETA, etanercept; IFX, infliximab; TNF, tumor necrosis factor.